Ypsomed Holding AG : Strong H1 2024-25 results and focus on fast-growing Delivery Systems division
>H1 figures above expectations– sale of Diabetes Care Business - At a group level, Ypsomed’s H1 sales of CHF 324m (+27%), were 9% above our (CHF 298m) and 7% above consensus estimates (CHF 304m). Just looking at continuing operations (the company sold its pen needle and blood glucose monitoring systems (BGM) business as of 31 July 2024, top line growth was even at 30%. Ypsomed’s adj. EBIT of CHF 65m (+44%) came in 15% higher than we expected (CHF57m) and was 7% above ...Ypsomed Holding operates in the field of medical technology and is an independent manufacturer of injection pens for pharmaceutical and biotech companies. Additionally, Co. supplies pen needles. Co.'s core business consists of developing and marketing products and services allowing patients to administer their own medication, in particular diabetes patients. Co. distributes its products worldwide by pharma and biotech companies under their own brand names. Co. operates production sites in Burgdorf, Solothurn, Grenchen and Tabor and has a sales and distribution network across Europe.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.